|
業務類別
|
-- |
|
業務概覽
|
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation. |
| 公司地址
| 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411 |
| 電話號碼
| +81 332443000 |
| 傳真號碼
| +81 352017473 |
| 公司網頁
| https://www.astellas.com |
| 員工數量
| 13643 |
| Mr. Katsuyoshi Sugita |
Director, Executive Vice President and Chief People Officer |
-- |
16/06/2025 |
| Mr. Naoki Okamura |
Director, President and Chief Executive Officer |
-- |
16/06/2025 |
|
|
| Ms. Tomoko Aramaki |
Independent Director |
16/06/2025 |
| Mr. Masahiro Miyazaki |
Independent Director |
16/06/2025 |
| Mr. Katsuyoshi Sugita |
Director, Executive Vice President and Chief People Officer |
16/06/2025 |
| Mr. Yoichi Ohno |
Independent Director |
16/06/2025 |
| Mr. Rie Akiyama |
Independent Director |
16/06/2025 |
| Mr. Mark Joseph Enyedy |
Independent Director |
16/06/2025 |
| Ms. Mika Nakayama |
Independent Director |
16/06/2025 |
| Ms. Eriko Sakurai |
Independent Director |
16/06/2025 |
| Mr. Takashi Tanaka |
Independent Director |
16/06/2025 |
| Mr. Rika Hirota |
Director |
16/06/2025 |
| Mr. Kenji Yasukawa |
Chairman of the Board |
16/06/2025 |
| Mr. Naoki Okamura |
Director, President and Chief Executive Officer |
16/06/2025 |
| Dr. Andreas Busch, PhD |
Independent Director |
16/06/2025 |
|
|
|
|
